腹膜透析相关腹膜纤维化的研究进展  

Advances in Peritoneal Dialysis-Related Peritoneal Fibrosis

作　　者：张胜勋 徐璐[2] 杜保川 李新建[2] 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁医学院附属医院,山东 济宁

出　　处：《临床医学进展》2022年第2期820-827,共8页Advances in Clinical Medicine

摘　　要：近几年来慢性肾脏病(Chronic kidney disease, CKD)的患病率持续上升,据统计,我国CKD的患病率约10.8%,终末期肾病(End stage of renal disease, ESRD)患者高达300万,接受透析的约60万,其中腹膜透析患者约占14%。腹膜透析(Peritoneal dialysis, PD)有很大优势,但长期PD会使腹膜的结构和功能发生变化,引起腹膜纤维化,最终造成超滤衰竭(Ultrafiltration failure, UFF),这一过程是导致PD失败的主要原因。本文从PD相关性腹膜纤维化的发生机制入手,介绍诊断和治疗该病的最新研究进展,包括细胞、动物实验层面,中医药治疗等方面,为进一步研究PD相关腹膜纤维化的防治问题提供临床证据。In recent years, the prevalence of chronic kidney disease (CKD) has continued to rise, according to statistics, the prevalence of CKD in China is about 10.8%, end-stage kidney disease (ESRD) patients are as high as 3 million, about 600,000 people on dialysis, of which peritoneal dialysis patients account for about 14%. Peritoneal dialysis (PD) has great advantages, but long-term PD causes changes in the structure and function of the peritoneal membrane, causing peritoneal fibrosis and ultimately ultrafiltration failure (UFF), a process that is the main cause of PD failure. Starting with the mechanism of PD-related peritoneal fibrosis, this paper introduces the latest research progress in the diagnosis and treatment of the disease, including the experimental level of cells and animals, and the treatment of traditional Chinese medicine, so as to provide clinical evidence for further study of the prevention and treatment of PD-related peritoneal fibrosis.

关 键 词：腹膜透析 腹膜纤维化 腹膜炎 

分 类 号：R692[医药卫生—泌尿科学]